Tumor Mutational Burden (TMB)

Tumor Mutation Burden (TMB) is a pivotal Next-Generation Sequencing (NGS) biomarker in immuno-oncology that measures the total number of somatic mutations per megabase (mut/Mb) within a tumor's genomic sequence. Tumors exhibiting high TMB generate a greater abundance of novel, tumor-specific antigens (neoantigens). These neoantigens enhance host immune recognition, rendering the tumor significantly more responsive to Immune Checkpoint Inhibitor (ICI) therapies.

Key Features & Advantages

1. Immunotherapy Response Prediction: Accurately identifies cancer patients most likely to derive durable clinical benefit from anti-PD-1/PD-L1 therapies.
2. Tumor-Agnostic Biomarker: Provides therapeutic guidance across diverse solid tumor types (e.g., NSCLC, melanoma, urothelial carcinoma) independent of tissue origin.
3. Integrated Genomic Profiling: Delivers simultaneous reporting of Microsatellite Instability (MSI) status and key oncogenic driver mutations alongside TMB scoring.
4. Optimized Patient Selection: Prevents ineffective immunotherapy regimens in non-responders, reducing unnecessary toxicities and healthcare costs.
5. 
   

TMB-High vs. TMB-Low Comparison

Key Applications

1. Advanced Solid Tumor Management: Guiding immunotherapy decisions in refractory, recurrent, or metastatic solid malignancies.
2. Combination Immunotherapy Protocols: Evaluating candidates for dual checkpoint blockade or chemo-immunotherapy combination regimens.
3. Carcinogen-Induced Malignancies: Profiling tumors with high intrinsic mutation rates linked to environmental exposures (e.g., tobacco smoke, UV light).
4. Blood-Based TMB (bTMB): Calculating tumor mutation burden directly from circulating tumor DNA (ctDNA) when tissue biopsies are unattainable.
5. 
   

The Nucleus Genetics Advantage: Combining broad-target NGS panels aligned with international standards and sophisticated bioinformatic algorithms that strictly filter out germline variants, we deliver precise, clinically actionable TMB scores.